The role of comparative observational studies
The NEJM and The Lancet on 06 June retracted two non-randomised comparative studies, of anti-hypertensive therapy and of excess mortality from hydroxychloroquine or chloroquine with or without a macrolide for the treatment of COVID-19, respectively. WHO reported on 03 June that the hydroxychloroquine arm of the SOLIDARITY trial will continue following review by the data monitoring committee. OXON leads a group…
Read more
